---
title: 'Funding Daily Summary: What Happened on October 23, 2026'
headline: Lycia prices $318 million IPO to fund three protein degraders
description: The offering is intended to support medicines for allergic conditions
  and Graves’ disease.
url: https://thebench.bio/news/funding/2026-10-23
topic: funding
date: '2026-10-23'
covers:
- '2026-10-23'
date_published: '2026-10-23T12:02:12Z'
date_modified: '2026-10-23T12:02:12Z'
tags:
- Funding
sources: 1
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on October 23, 2026

**Lycia prices $318 million IPO to fund three protein degraders**

The offering is intended to support medicines for allergic conditions and Graves’ disease.

## Today in brief

Lycia priced a $318 million initial public offering to support three protein-degrading medicines in development. [1] The medicines are being developed for allergic conditions and Graves’ disease. [1]

## Lycia prices $318 million IPO for three drug programs

Lycia priced its initial public offering at $318 million. [1] Proceeds from the upsized offering are intended to support three protein-degrading medicines for allergic conditions and Graves’ disease. [1]

## The day in numbers

- **$318 million**: Value of Lycia’s priced initial public offering. [1]
- **Three**: Protein-degrading medicines the offering proceeds are intended to support. [1]

## Sources

1. [Protein degrader specialist Lycia prices $318M IPO](<https://www.biopharmadive.com/news/lycia-therapeutics-targeted-protein-degraders-ipo-pricing/833624/>), BioPharma Dive, 2026-10-23

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biopharmadive.com/news/lycia-therapeutics-targeted-protein-degraders-ipo-pricing/833624/>